ConductScience.org, home

Paper2864056

Celiprolol: pharmacokinetics and duration of pharmacodynamic activity.

Caruso FS and 5 others. Br J Clin Pract Suppl, 1985. Cited by 38 papers, by iCite.

Cite this record

ConductScience Library. Celiprolol: pharmacokinetics and duration of pharmacodynamic activity. Papers, record 2864056. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2864056

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Celiprolol: pharmacokinetics and duration of pharmacodynamic activity.
PubMed
Journal
Br J Clin Pract Suppl
PubMed
Year
1985
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
1.69
iCite
Revised in PubMed
2013-11-21
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Caruso FSF S
2Doshan HDH D
3Hernandez PHP H
4Costello RR
5Applin WW
6Neiss ESE S

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adrenergic beta-AntagonistsMajor topic
PropanolaminesMajor topic
Celiprolol
Humans
Kinetics
Time Factors

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
39064294Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers-Danlos Syndrome: Focus on Vascular Prevention.J Clin Med2024https://conductscience.org/library/papers/39064294PubMed
35245290Comparative therapeutic strategies for preventing aortic rupture in a mouse model of vascular Ehlers-Danlos syndrome.PLoS Genet2022https://conductscience.org/library/papers/35245290PubMed
34112223Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.Crit Care2021https://conductscience.org/library/papers/34112223PubMed
34009624Analysis of Non-linear Pharmacokinetics of P-Glycoprotein Substrates in a Microfluidic Device Using a Mathematical Model that Includes an Unstirred Water Layer (UWL) Compartment.Pharm Res2021https://conductscience.org/library/papers/34009624PubMed
31789518Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.J Med Chem2020https://conductscience.org/library/papers/31789518PubMed
31030372Predictive Value of Microdose Pharmacokinetics.Clin Pharmacokinet2019https://conductscience.org/library/papers/31030372PubMed
28742547Celiprolol: A Unique Selective Adrenoceptor Modulator.Cardiol Rev2017https://conductscience.org/library/papers/28742547PubMed
20135207Model analysis of the concentration-dependent permeability of P-gp substrates.Pharm Res2010https://conductscience.org/library/papers/20135207PubMed
8834196Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.J Pharmacokinet Biopharm1995https://conductscience.org/library/papers/8834196PubMed
8573993Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.Drugs Aging1995https://conductscience.org/library/papers/8573993PubMed
8058631The contribution of intestinal secretion to the dose-dependent absorption of celiprolol.Pharm Res1994https://conductscience.org/library/papers/8058631PubMed
7913813A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.Drug Saf1994https://conductscience.org/library/papers/7913813PubMed
7905337Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein.Br J Pharmacol1993https://conductscience.org/library/papers/7905337PubMed
2968268Comparison of the antihypertensive effects of celiprolol and acebutolol.Eur J Clin Pharmacol1988https://conductscience.org/library/papers/2968268PubMed
2908720Hemodynamic effects of celiprolol at rest and during exercise; a comparison with enalapril.Cardiovasc Drugs Ther1988https://conductscience.org/library/papers/2908720PubMed
2899439Importance of ancillary properties of beta blockers in angina: a study of celiprolol and atenolol.Br Heart J1988https://conductscience.org/library/papers/2899439PubMed
2890513Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.Drugs1987https://conductscience.org/library/papers/2890513PubMed
2566321Comparison of the cardiovascular and pulmonary effects of oral celiprolol, propranolol and placebo in normal volunteers.Br J Clin Pharmacol1989https://conductscience.org/library/papers/2566321PubMed
2150174Effect of celiprolol on large and small arteries of the forearm circulation in hypertensive patients.Cardiovasc Drugs Ther1990https://conductscience.org/library/papers/2150174PubMed
1982763Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function.Eur J Clin Pharmacol1990https://conductscience.org/library/papers/1982763PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2864056

GET https://conductscience.org/api/papers/v1/2864056/cited_by?page=2